Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years

NCT02733068 is registered in ClinicalTrials.gov with Shanghai Zerun Biotechnology Co.,Ltd as lead sponsor.

NCT NCT02733068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02733068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years
Lead sponsor
Shanghai Zerun Biotechnology Co.,Ltd
Phase
Phase 3
Overall status
Completed
Start date
November 2, 2014
Completion date
January 16, 2020
Enrollment
12,000 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cervical intraepithelial neoplasia, human papilloma virus infection type 16, human papilloma virus infection type 18